RNXT RenovoRx, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1574094 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-17.2%
TTM EPS YoY13.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin84.0%
Operating margin-489.0%
Net margin-469.0%
FCF margin-440.4%
EBITDA margin-416.6%
Returns
ROE-150.0%
ROA-110.1%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets25.4%
Debt / equity0.00x
Current ratio5.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.12M | $43,000 | — | — | — |
| Cost of revenue | $327,000 | $0 | — | — | — |
| Gross profit | $796,000 | $43,000 | — | — | — |
| R&D expense | $6.27M | $6.03M | $5.67M | $4.30M | $3.04M |
| SG&A expense | $7.04M | $4.99M | $5.73M | $5.65M | $2.63M |
| Operating income | -$12.51M | -$10.97M | -$11.40M | -$9.95M | -$5.67M |
| Pretax income | -$11.17M | -$8.75M | — | — | — |
| Income tax | $2,000 | — | — | — | — |
| Net income | -$11.17M | -$8.81M | -$10.23M | -$9.89M | -$6.32M |
| EBITDA | -$10.51M | -$10.97M | — | — | — |
| EPS (basic) | -0.32 | -0.40 | -0.99 | -1.09 | -1.21 |
| EPS (diluted) | -0.32 | -0.40 | -0.99 | -1.09 | -1.21 |
| Weighted avg. shares (diluted) | 35.33M | 22.27M | 10.29M | 9.05M | 5.22M |
| Banking | |||||
| Net interest income | — | — | — | — | -$834,000 |
| Balance sheet | |||||
| Cash & equivalents | $7.02M | $7.15M | $1.17M | $4.39M | $15.19M |
| Short-term investments | — | — | — | $2.05M | — |
| Receivables | $139,000 | $43,000 | — | — | — |
| Inventory | $189,000 | $0 | — | — | — |
| Current assets | $7.89M | $7.83M | $1.47M | $7.26M | $16.28M |
| PP&E, net | $12,000 | $12,000 | — | — | — |
| Total assets | $8.10M | $8.12M | $1.47M | $7.26M | $16.29M |
| Current liabilities | $1.96M | $1.91M | $1.18M | $1.10M | $938,000 |
| Total liabilities | $2.67M | $3.64M | $4.47M | $1.10M | $938,000 |
| Shareholders' equity | $5.42M | $4.48M | $3.00M | $6.16M | $15.35M |
| Shares outstanding | 36.61M | 24.03M | 10.69M | 9.10M | 8.93M |
| Cash flow statement | |||||
| Operating cash flow | -$10.97M | -$9.12M | -$10.26M | -$8.81M | -$5.92M |
| Capital expenditure | $2,000 | $12,000 | — | — | — |
| Free cash flow | -$10.97M | -$9.14M | — | — | — |
| Investing cash flow | -$2,000 | -$12,000 | $2.03M | -$2.03M | -$15,000 |
| Financing cash flow | $10.85M | $15.12M | $5.01M | $42,000 | $19.33M |
| Depreciation & amortization | $2.00M | $0 | — | — | — |
| Stock-based compensation | $1.27M | $1.17M | $1.08M | $644,000 | $147,000 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.